The Many Faces Of mCRPC- Assessing Patient Profiles and Tailoring Treatment in a Changing Landscape

Summary of Presentations from the Bayer Healthcare Symposium, held at the 29th Annual EAU Congress, Stockholm, Sweden, on 11th April 2014

Chairperson: Manfred Wirth1
Speakers: Fred Saad,2 Joe O’Sullivan,3 Anders Bjartell,4 Wolfgang Loidl5

1. University Hospital Carl Gustav Carus Dresden and Technical University of Dresden, Dresden, Germany
2. Centre Hospitalier de l’Université de Montréal, Montréal, Canada
3. Centre for Cancer Research and Cell Biology, Queen’s University Belfast and
Northern Ireland Cancer Centre, Belfast, UK
4. Lund University, Malmö, Sweden
5. St Vincent’s Hospital, Linz, Austria

Disclosure: Speakers participating in this symposium received honorarium from Bayer Healthcare.
Acknowledgements: Writing assistance provided by Dr Tabasum Mughal.
Support: The publication of this article was funded by Bayer Healthcare. The views and opinions expressed are those of the authors and not necessarily of Bayer Healthcare.
Citation: EMJ Urol. 2014;1:28-32.

Meeting Summary

The Bayer-sponsored satellite symposium brought together a range of experts in the field of metastatic castrate-resistant prostate cancer (mCRPC), including Professors Fred Saad, Joe O’Sullivan, Anders Bjartell, Wolfgang Loidl, and Manfred Wirth. This distinguished faculty came together to discuss the changing paradigm and therapeutic options available in the management of mCRPC, offering the opportunity for interactive audience participation to discuss the current treatment landscape.

Download (PDF, 77KB)

Comments are closed.